937047-04-6

Basic information

• Product Name: 1-N-BOC-AMINO-4-BROMO-2-CYANO-1H-PYRROLE
• Synonyms: 1-N-BOC-AMINO-4-BROMO-2-CYANO-1H-PYRROLE;CarbaMic acid, N-(4-broMo-2-cyano-1H-pyrrol-1-yl)-, 1,1-diMethylethyl ester;tert-Butyl (4-bromo-2-cyano-1H-pyrrol-1-yl)carbamate
• CAS NO: 937047-04-6
• Molecular Formula: C10H12BrN3O2
• Molecular Weight: 286.12518
• Mol File: 937047-04-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-N-BOC-AMINO-4-BROMO-2-CYANO-1H-PYRROLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-AMINO-4-BROMO-2-CYANO-1H-PYRROLE(937047-04-6)
• EPA Substance Registry System: 1-N-BOC-AMINO-4-BROMO-2-CYANO-1H-PYRROLE(937047-04-6)

Safety Data

• Hazardous Substances Data: 937047-04-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-N-BOC-Amino-4-bromo-2-cyano-1H-pyrrole is used as a synthetic intermediate for the development of pharmaceutical compounds. The BOC-protected amino group allows for further functionalization and modification of the molecule, while the bromine and cyano groups contribute to the synthesis of a wide range of heterocyclic and bioactive compounds.
Used in Agrochemical Industry:
1-N-BOC-Amino-4-bromo-2-cyano-1H-pyrrole is used as a key building block in the synthesis of agrochemicals. Its unique structure and functional groups enable the creation of novel agrochemicals with improved properties and effectiveness in crop protection and pest management.

Upstream product

• 5176-27-2 N-tert-butyloxycarbonyl-pyrrole 
• 937046-95-2 N-(1H-pyrrol-1-yl)-carbamic acid tert-butyl ester 
• 870-46-2 t-butoxycarbonylhydrazine 
• 937046-96-3 tert-butyl (2-cyano-1H-pyrrol-1-yl)carbamate 

Downstream Products

• 937047-05-7 1-amino-4-bromo-1H-pyrrole-2-carbonitrile hydrochloride 
• 1201784-90-8 6-bromopyrrolo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione 

Relevant articles and documents

FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF

Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.

THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF

Compound (III) which is the crystalline form of [4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-l-benzothiophen-2-yl)pyrrolo[2, -f] [ 1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride] which is the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and its use in the control of disorders, including cancer.

CDK kinase inhibitors

The invention discloses a compound with the general formula (I) and a salt thereof, wherein the compound can be taken as inhibitors of CDK kinase, particularly CDK4/6 kinase, and all variables are defined in the invention. The compound can be used for treating or preventing diseases such as cancer. The present application also relates to pharmaceutical compositions comprising the compound of formula (I).

Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor

Rogaratinib (BAY 1163877) is a highly potent and selective small-molecule pan-fibroblast growth factor receptor (FGFR) inhibitor (FGFR1–4) for oral application currently being investigated in phase 1 clinical trials for the treatment of cancer. In this publication, we report its discovery by de novo structure-based design and medicinal chemistry optimization together with its pharmacokinetic profile.

PYRROLOTRIAZINE COMPOUNDS

A compound of formula (I), wherein all symbols have the same meanings as defined in the specification; a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, has a Btk inhibitory activity, and is useful as a method for preventing and

SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.